Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
05:34pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.
Halozyme (HALO) to Acquire Antares for Auto Injector Platform
02:06pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.
M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus
02:03pm, Thursday, 14'th Apr 2022 Zacks Investment Research
We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates fo
Best Biotech Stocks To Buy Now? 5 To Know
01:50pm, Thursday, 14'th Apr 2022
Check out these biotech stocks with exciting developments today.
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes
01:28pm, Wednesday, 13'th Apr 2022 PennyStocks
Here's what you need to know about trading penny stocks on April 13th
The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Info
Why Antares Pharma Stock Is Bolting Higher Today
12:33pm, Wednesday, 13'th Apr 2022 The Motley Fool
The drug delivery specialist has reportedly agreed to a merger with Halozyme.
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity
07:52am, Wednesday, 13'th Apr 2022
Halozyme Therapeutics Inc (NASDAQ: HALO) will acquire Antares Pharma Inc (NASDAQ: ATRS) for $5.60 per share, valuing Antares at approximately $960 million. The transaction is expected to be accre
Antares Pharma stock rockets after Halozyme buyout deal for a near-50% premium
06:12am, Wednesday, 13'th Apr 2022
Shares of Antares Pharma Inc. ATRS, -0.27% rocketed 46.3% in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeu
Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition
12:24pm, Wednesday, 06'th Apr 2022 Zacks Investment Research
Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive rev
Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition
09:47am, Wednesday, 06'th Apr 2022
Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive rev
Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma
01:47pm, Friday, 25'th Mar 2022 Zacks Investment Research
Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.
Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma
11:17am, Friday, 25'th Mar 2022
Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.
Halozyme Therapeutics (HALO) Up 11.4% Since Last Earnings Report: Can It Continue?
12:47pm, Thursday, 24'th Mar 2022
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
argenx (ARGX) Up on Positive Autoimmune Disorder Study Data
12:42pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.
Is Halozyme Therapeutics (HALO) A Worthy Long-Term Investment?
04:00am, Monday, 28'th Feb 2022 Insider Monkey
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here.
